Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
77,937.49
(
-1.42%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 158668

Wednesday, 06/05/2013 6:46:17 AM

Wednesday, June 05, 2013 6:46:17 AM

Post# of 257579
Galderma enters the Botox-like botulinum-toxin market:

http://finance.yahoo.com/news/galderma-initiates-clinical-development-novel-053000443.html

Current players in this market are AGN (Botox), VRX/Ipsen (Dysport), and Merz (Xeomin); Botox has about an 80% worldwide combined market share in all applications (medical and cosmetic).

JNJ has a Botox-like product in phase-3 called PurTox (see #msg-85982909 and ensuing Reply chain).

Galderma, which also owns the rights to the Restylane family of dermal fillers, is a 50/50 JV of Nestlé and L’Oreal.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today